Clene (NASDAQ:CLNN) versus Liquidia (NASDAQ:LQDA) Head to Head Analysis

Liquidia (NASDAQ:LQDA) and Clene (NASDAQ:CLNN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and target prices for Liquidia and Clene, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2	1	7	2	2.75
Clene	1	0	6	0	2.71

Liquidia currently has a consensus price target of $42.00, suggesting a potential upside of 8.16%. Clene has a consensus price target of $32.60, suggesting a potential upside of 499.26%. Given Clene’s higher possible upside, analysts plainly believe Clene is more favorable than Liquidia.

Risk and Volatility

Liquidia has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Profitability

This table compares Liquidia and Clene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Liquidia	-43.53%	-209.33%	-25.32%
Clene	-14,250.47%	N/A	-140.71%

Insider and Institutional Ownership

64.5% of Liquidia shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 30.1% of Liquidia shares are held by company insiders. Comparatively, 35.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Liquidia and Clene”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32 million	21.61	-$68.92 million	($0.83)	-46.78
Clene	$340,000.00	173.60	-$39.40 million	($3.39)	-1.60

Clene has lower revenue, but higher earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Summary

Liquidia beats Clene on 8 of the 15 factors compared between the two stocks.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.